p53 mutations and microsatellite instability in ovarian cancer: Yin and Yang

被引:16
作者
Buller, RE
Shahin, MS
Holmes, RW
Hatterman, M
Kirby, PA
Sood, AK
机构
[1] Univ Iowa Hosp & Clin, Dept Obstet & Gynecol, Div Gynecol Oncol, Iowa City, IA 52242 USA
[2] Univ Iowa Hosp & Clin, Dept Pathol, Iowa City, IA 52242 USA
关键词
p53; microsatellite instability; ovarian cancer;
D O I
10.1067/mob.2001.113856
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
OBJECTIVE: We tested the hypothesis that p53 frameshift mutations in ovarian cancer occur as a result of genomic instability rather than as a proximal cause of this process. STUDY DESIGN: Sequencing of the p53 tumor suppressor gene has been carried out on 305 ovarian, fallopian tube, and peritoneal cancers. Two groups of p53 null mutations were identified: (1) those caused by frameshift insertion or deletion mutations (n = 31) and (2) those caused by nonsense mutations (n = 28). As a control group 59 tumors with p53 missense mutations were selected by matching with the p53 null tumors on the basis of patient age at diagnosis, stage and grade of cancer, cancer site, and year of diagnosis. Microsatellite instability was determined from paired normal and tumor tissue deoxyribonucleic acid by means of the following different markers: D2S123, D5S346, D17S250, BAT25, and BAT26. Amplimers from polymerase chain reactions were evaluated on 7% polyacrylamide gels. RESULTS: The p53 null tumors were more likely to be of higher stage and grade. Fallopian tube cancers were more common (P =.02) in the p53 frameshift group. The overall incidence of microsatellite instability was 39%, 36%, and 25% for tumors with p53 frameshift nonsense and missense mutations (P =.30). Microsatellite instability was seen almost exclusively with ovarian cancer (P=.04). CONCLUSIONS: Microsatellite instability is a relatively common event in ovarian cancer and is dependent on marker selection. The p53 frameshift mutations do not appear to occur as a consequence of genomic instability.
引用
收藏
页码:891 / 902
页数:12
相关论文
共 59 条
[1]   Maintenance of genomic integrity by p53:: complementary roles for activated and non-activated p53 [J].
Albrechtsen, N ;
Dornreiter, I ;
Grosse, F ;
Kim, E ;
Wiesmüller, L ;
Deppert, W .
ONCOGENE, 1999, 18 (53) :7706-7717
[2]  
Anthoney DA, 1996, CANCER RES, V56, P1374
[3]  
Boland CR, 1998, CANCER RES, V58, P5248
[4]   Interaction of p53 with the human Rad51 protein [J].
Buchhop, S ;
Gibson, MK ;
Wang, XW ;
Wagner, P ;
Sturzbecher, HW ;
Harris, CC .
NUCLEIC ACIDS RESEARCH, 1997, 25 (19) :3868-3874
[5]   Association between nonrandom X-chromosome inactivation and BRCA1 mutation in germline DNA of patients with ovarian cancer [J].
Buller, RE ;
Sood, AK ;
Lallas, T ;
Buekers, T ;
Skilling, JS .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (04) :339-346
[6]   Field cancerization: Why late "recurrent" ovarian cancer is not recurrent [J].
Buller, RE ;
Skilling, JS ;
Sood, AK ;
Plaxe, S ;
Baergen, RN ;
Lager, DJ .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 178 (04) :641-649
[7]  
Buller RE, 1999, CANCER GENE THER, V6, pS4
[8]   ABSENCE OF SIGNIFICANT GERM-LINE P53 MUTATIONS IN OVARIAN-CANCER PATIENTS [J].
BULLER, RE ;
SKILLING, JS ;
KALISZEWSKI, S ;
NIEMANN, T ;
ANDERSON, B .
GYNECOLOGIC ONCOLOGY, 1995, 58 (03) :368-374
[9]   DNA repair: Enzymatic mechanisms and relevance to drug response [J].
Chaney, SG ;
Sancar, A .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (19) :1346-1360
[10]   Tumorigenesis and a DNA repair defect in mice with a truncating Brca2 mutation [J].
Connor, F ;
Bertwistle, D ;
Mee, PJ ;
Ross, GM ;
Swift, S ;
Grigorieva, E ;
Tybulewicz, VLJ ;
Ashworth, A .
NATURE GENETICS, 1997, 17 (04) :423-430